Publications by authors named "Iseult M Browne"
Cancers (Basel)
June 2024
Article Synopsis
- The PI3K/AKT/mTOR signaling pathway is crucial in breast cancer and other bodily functions, with ongoing research focused on developing inhibitors for this pathway in advanced breast cancer treatment.
- Currently, only three inhibitors—everolimus, alpelisib, and capivasertib—are approved for use against this pathway in ER-positive, HER2-negative breast cancer, but drug resistance remains a significant challenge.
- Resistance can be intrinsic (existing before treatment) or acquired (developing during treatment), affecting most patients and highlighting the need for more research on resistance mechanisms and management strategies, particularly concerning AKT1 inhibitors.*
Article Synopsis
- The availability of targeted therapies for advanced oestrogen receptor-positive breast cancer has improved patient survival, but optimal management strategies are still being explored.
- Key pathways involved in breast cancer, specifically PI3K-AKT and mTOR, have led to the development of specific inhibitors like alpelisib, capivasertib, and everolimus for tailored treatment.
- This review aims to summarize the understanding of these pathways and inhibitors, and to propose strategies for effectively sequencing therapies, especially after patients progress on CDK4/6 inhibitors.
